Intraocular Lens Postmarket Surveillance Supported By Ophthalmic Panelists
This article was originally published in The Gray Sheet
Executive Summary
Postmarket surveillance for phakic intraocular lenses (IOLs) is largely favored by members of FDA's Ophthalmic Devices Panel, although recommended duration could vary depending on risk